Sanofi

See the following -

CEO Roundtable On Cancer Launches The Project Data Sphere Initiative, A New Data Sharing And Analytic Platform For Cancer Patient Benefit

Press Release | CEO Roundtable on Cancer , SAS, Sage Bionetworks | April 8, 2014

Project Data Sphere, LLC (PDS), an independent not-for-profit initiative of the CEO Roundtable on Cancer’s Life Sciences Consortium (LSC), announced today the launch of a new data sharing platform (www.ProjectDataSphere.org), with the goal of advancing research to improve the lives of cancer patients and their families around the world...

Read More »

Crowdsourcing a Better Prostate Cancer Prediction Tool

Press Release | University of Colorado Anschutz Medical Campus | November 15, 2016

Knowing the likely course of cancer can influence treatment decisions. Now a new prediction model published today in Lancet Oncology offers a more accurate prognosis for a patient's metastatic castration-resistant prostate cancer. The approach was as novel as the result - while researchers commonly work in small groups, intentionally isolating their data, the current study embraces the call in Joe Biden's "Cancer Moonshot" to open their question and their data, collecting previously published clinical trial data and calling for worldwide collaboration to evaluate its predictive power...

Read More »

Doctors Promoting Treatments on Social Media Routinely Fail to Disclose Ties to Drug Makers

Sheila Kaplan | STAT | February 29, 2016

Physicians across the United States routinely offer medical advice on social media — but often fail to mention that they have accepted tens and sometimes hundreds of thousands of dollars from the companies that make the prescription drugs they tout. A STAT examination of hundreds of social media accounts shows that health care professionals virtually never note their conflicts of interest, some of them significant, when promoting drugs or medical devices on sites such as Facebook, Instagram, and Twitter. The practice cuts across all specialties...

Read More »

Gathering a Health Care Industry Around an Open Source Solution: the Success of tranSMART

Andy Oram | EMR & EHR | May 18, 2015

The role of open source software in healthcare is relatively hidden and uncelebrated, but organizations such as the tranSMART Foundation prove that it is making headway behind the scenes. tranSMART won three awards at the recent Bio‐IT World conference, including Best in Show. The tranSMART Foundation is a non‐profit organization that develops creates software for translational research, performing tasks such as searching for patterns in genomes and how they are linked to clinical outcomes. Like most of the sustainable, highly successful open source projects, tranSMART avoids hiring programmers to do the work itself, but fosters a sense of community by coordinating more than 100 developers from the companies who benefit from the software.

Read More »

How Google Plans to Reinvent Healthcare

Cheryl Swanson | The Motley Fool | September 3, 2016

Glucose-monitoring contact lenses for diabetics, wrist computers that read diagnostic nanoparticles injected in the blood stream, implantable devices that modify electrical signals that pass along nerves, medication robots, human augmentation, human brain simulation -- the list goes on. That's not an inventory of improbable CGI effects from the latest sci-fi movie, it's a list of initiatives being tackled by Alphabet's Google Life Sciences research unit, recently rebranded Verily...

Read More »

Life Science and IT Organizations Invest in the tranSMART Foundation to Advance Translational Medicine Research

Press Release | The tranSMART Foundation | January 14, 2015

The tranSMART Foundation, a non-profit organization providing a global, open-source knowledge management platform for scientists to share pre-competitive translational research data, today announced that 20 life sciences and technology organizations have made substantial commitments by joining its Membership Program. Read More »

Research Symbiosis Makes Mathematical Crystal Ball to Gaze into Future of Prostate Cancer Treatment

Press Release | University of Colorado Cancer Center | August 4, 2017

The chemotherapy docetaxel is widely accepted as a standard therapy for metastatic castration-resistant prostate cancer. But 10-20 percent of patients will have adverse side effects that force discontinuation of treatment. These patients may have been better off with another treatment in the first place, but who’s to know before trying the drug which patients will go on to experience debilitating side effects? A crowdsourced competition asked this as an open question. Today in the Journal of Clinical Oncology Clinical Cancer Informatics, competition organizers and participating teams report their findings...

Read More »

The tranSMART Foundation To Hold International Developers Meeting For Its Open-Source Translational Medicine Research Platform

Press Release | tranSMART Foundation | February 6, 2014

The tranSMART Foundation, a non-profit organization providing a global, open-source knowledge management platform for scientists to share pre-competitive translational research data, today announced that it is hosting an International Developers Meeting February 5-7, 2014 at Recombinant by Deloitte's location in Newton, Mass. Read More »

Transitioning To Open Systems In Drug Discovery

John Wilbanks | FasterCures | October 18, 2013

Bringing the ideas of “open source” into the pharmaceutical process is far from simple. It requires a careful understanding both of the realities of open source as a software development process well as the realities of therapy research, development, and regulatory approval. Read More »

What Clinical Trial Results? Now You Can See Who Isn’t Sharing Their Findings

Ed Silverman | STAT | November 3, 2016

The results for nearly half of all clinical trials conducted by big drug makers during the last decade have not been published, and one company — Ranbaxy Laboratories — has not published findings for any of the nearly three dozen trials conducted in the past 10 years, according to a new online tool. The tool was launched Thursday by AllTrials, a consortium of researchers and medical journals that has been pushing the pharmaceutical industry to do a better job of disclosing clinical trial data...

Read More »

“Open Source” Drug Discovery - €196M Program Launched

Ben Steele | eyeforpharma | February 8, 2013

Major pharma firms have joined together in a consortium with academics and SMEs that will invest €196 million in a new project to give a boost to ‘open-source’ drug discovery in the EU. Read More »